Spl-lacosamide-figure-1 (Spl Lacosamide Figure 1)
This text presents a chart showing the median percentage reduction in seizure frequency per 28 days from baseline to the maintenance phase by dose in three different studies comparing placebo to Lacosamide at doses of 200, 400, and 600 mg/day. The results indicate that Lacosamide was associated with a statistically significant reduction in seizure frequency compared to placebo in all three studies.*